www.drugdevelopment-technology.com
News, views and contacts from the global Drugdevelopment industry
28 July 2017
WEEKLY UPDATE
Digital Magazine
Latest Companies

Biovian - Contract Manufacturing Of Biopharmaceuticals

Pfanstiehl - Injectable and HPLE Carbohydrates for Protein Stabilisation and Optimisation

Malvern Instruments - Biopharmaceutical and Drug Development

Sartorius - Biopharmaceutical Laboratory Equipment and Integrated Bioprocess Services

ImmunoPrecise Antibodies - Custom Monoclonal and Polyclonal Antibody Development

Press Releases

Powerful Benchtop Spectrometer for Small Spot Analysis
Supplier of analytical X-ray instrumentation and software PANalytical has announced the introduction of a new Epsilon 1 X-ray fluorescence (XRF) spectrometer.

Huge New Opportunity in Generic Drug Development Created by US FDA
The US market is to gain access to previously unavailable therapeutically equivalent generic drug formulations due to a number of changes.

Tailoring the Properties of New Compounds Using XRD Data Analysis
Understanding the make-up of crystalline structures is a vital aspect of the characterisation of new compounds, and can be regarded as an important first step towards the possibility of tailoring its properties.

Upcoming Events Malvern
Malvern will be hosting a wide range of webinars throughout July and August.

Breaking Down Complex Generics
Pharmaceutical consulting and generic drug professionals: What is your hedge against the increasingly crowded traditional drug markets?

White Papers

Customised Crystallisation and Filtration System
Systag's crystallisation and filtration system helps increase your flexibility, productivity, and optimises your...

Drug Labeling Specialist on New Pregnancy Labeling Rules
On 30 June, 2015, new pregnancy labeling rules for prescription drugs took effect, marking the demise of pregnancy categories (A, B, C, D, X), which have been in use since...

Sartorius Lab Instrument's Cubis® Balance Range Meets the Cleanability Requirements of the Pharmaceutical Industry
Balances in Satorius Lan Instrument's Cubis® product range have been designed for the demanding pharmaceutical environment, which is regulated by good manufacturing practices (GMP) and...

Gold Nanoparticle Applications and Characterisation by Nanoparticle Tracking Analysis
Gold nanoparticles are one of the most popular and extensively researched type of...

Characterisation Information of Critical Excipients for Sourcing Critical Raw Materials
The increasing complexity of large molecule and cell-based therapeutics calls for an evolution in our understanding of the impurity and functional contributions of each formulation...

Features

June’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly’s empagliflozin trial
A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic kidney disease. Drugdevelopment-technology.com wraps up the key headlines from June.

May's top stories: Funders and NGOs agreed on new standards, Actinogen's Xanamem in Phase II
Medical research funders and international NGOs agreed to implement the new WHO standards for clinical trials, and Actinogen Medical began patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer’s disease. Drugdevelopment-technology.com wraps up the key headlines from May.

April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial
The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of nintedanib to treat various progressive fibrosing lung diseases. Drug development-technology.com wraps up the key headlines from April.

March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis
Cancer Research UK invested £10m in the PRECISION Panc project, including a network of clinical trials for the treatment of pancreatic cancer, and Novartis reported positive results from the extension A2302E1 trial of Cosentyx to modify the course of psoriasis. Drugdevelopment-technology.com wraps up the key headlines from March.

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial
Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v to prevent mosquito-transmitted diseases. Drugdevelopment-technology.com wraps up the key headlines from February.

Projects

Tremfya (guselkumab) for the Treatment of Plaque Psoriasis
Tremfya™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis.

Endari for the Treatment of Sickle Cell Disease
Endari™ is an orally-administered powder form of amino acid L-glutamine indicated for the treatment of sickle cell disease.

Haegarda for the Preventive Treatment of Hereditary Angioedema
Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Ligand Pharmaceuticals.

Zykadia (Ceritinib) Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
Zykadia (Ceritinib / LDK378) is an inhibitor of anaplastic lymphoma kinase (ALK) indicated for treatment of non-small cell lung cancer (NSCLC).

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.